首页 > 最新文献

PROTEOMICS – Clinical Applications最新文献

英文 中文
A protein microarray-based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer. 一项基于蛋白质微阵列的血清蛋白质组学研究揭示了结直肠癌中独特的自身抗体特征。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-03-01 DOI: 10.1002/prca.202200062
Abhilash Barpanda, Chaitanya Tuckley, Arka Ray, Arghya Banerjee, Siddhartha P Duttagupta, Chetan Kantharia, Sanjeeva Srivastava

Purpose: Colorectal cancer (CRC) has been reported as the second leading cause of cancer death worldwide. The 5-year annual survival is around 50%, mainly due to late diagnosis, striking necessity for early detection. This study aims to identify autoantibody in patients' sera for early screening of cancer.

Experimental design: The study used a high-density human proteome array with approximately 17,000 recombinant proteins. Screening of sera from healthy individuals, CRC from Indian origin, and CRC from middle-east Asia origin were performed. Bio-statistical analysis was performed to identify significant autoantibodies altered. Pathway analysis was performed to explore the underlying mechanism of the disease.

Results: The comprehensive proteomic analysis revealed dysregulation of 15 panels of proteins including CORO7, KCNAB1, WRAP53, NDUFS6, KRT30, and COLGALT2. Further biological pathway analysis for the top dysregulated autoantigenic proteins revealed perturbation in important biological pathways such as ECM degradation and cytoskeletal remodeling etc. CONCLUSIONS AND CLINICAL RELEVANCE: The generation of an autoimmune response against cancer-linked pathways could be linked to the screening of the disease. The process of immune surveillance can be detected at an early stage of cancer. Moreover, AAbs can be easily extracted from blood serum through the least invasive test for disease screening.

目的:结直肠癌(CRC)已被报道为全球癌症死亡的第二大原因。5年生存率约为50%,主要是由于晚期诊断,早期发现的必要性。本研究旨在检测患者血清中的自身抗体,用于癌症的早期筛查。实验设计:该研究使用高密度人类蛋白质组阵列,其中包含约17,000个重组蛋白。筛查来自健康个体、印度CRC和中东亚洲CRC的血清。进行生物统计学分析以确定显著的自身抗体改变。通过通路分析来探索该疾病的潜在机制。结果:综合蛋白质组学分析显示,CORO7、KCNAB1、WRAP53、NDUFS6、KRT30、COLGALT2等15组蛋白出现异常。进一步的生物通路分析显示,在一些重要的生物通路中,如ECM降解和细胞骨架重塑等都受到了干扰。结论和临床意义:针对癌症相关途径的自身免疫反应的产生可能与疾病的筛查有关。免疫监视的过程可以在癌症的早期阶段检测到。此外,通过最小侵入试验,可以很容易地从血清中提取自身抗体,用于疾病筛查。
{"title":"A protein microarray-based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer.","authors":"Abhilash Barpanda,&nbsp;Chaitanya Tuckley,&nbsp;Arka Ray,&nbsp;Arghya Banerjee,&nbsp;Siddhartha P Duttagupta,&nbsp;Chetan Kantharia,&nbsp;Sanjeeva Srivastava","doi":"10.1002/prca.202200062","DOIUrl":"https://doi.org/10.1002/prca.202200062","url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer (CRC) has been reported as the second leading cause of cancer death worldwide. The 5-year annual survival is around 50%, mainly due to late diagnosis, striking necessity for early detection. This study aims to identify autoantibody in patients' sera for early screening of cancer.</p><p><strong>Experimental design: </strong>The study used a high-density human proteome array with approximately 17,000 recombinant proteins. Screening of sera from healthy individuals, CRC from Indian origin, and CRC from middle-east Asia origin were performed. Bio-statistical analysis was performed to identify significant autoantibodies altered. Pathway analysis was performed to explore the underlying mechanism of the disease.</p><p><strong>Results: </strong>The comprehensive proteomic analysis revealed dysregulation of 15 panels of proteins including CORO7, KCNAB1, WRAP53, NDUFS6, KRT30, and COLGALT2. Further biological pathway analysis for the top dysregulated autoantigenic proteins revealed perturbation in important biological pathways such as ECM degradation and cytoskeletal remodeling etc. CONCLUSIONS AND CLINICAL RELEVANCE: The generation of an autoimmune response against cancer-linked pathways could be linked to the screening of the disease. The process of immune surveillance can be detected at an early stage of cancer. Moreover, AAbs can be easily extracted from blood serum through the least invasive test for disease screening.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Plasma proteomics identify potential severity biomarkers from COVID-19 associated network. 血浆蛋白质组学从COVID-19相关网络中确定潜在的严重程度生物标志物。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-03-01 DOI: 10.1002/prca.202200070
Ayse Tugce Sahin, Ali Yurtseven, Sina Dadmand, Gulin Ozcan, Busra A Akarlar, Nazli Ezgi Ozkan Kucuk, Aydanur Senturk, Onder Ergonul, Fusun Can, Nurcan Tuncbag, Nurhan Ozlu

Purpose: Coronavirus disease 2019 (COVID-19) continues to threaten public health globally. Severe acute respiratory coronavirus type 2 (SARS-CoV-2) infection-dependent alterations in the host cell signaling network may unveil potential target proteins and pathways for therapeutic strategies. In this study, we aim to define early severity biomarkers and monitor altered pathways in the course of SARS-CoV-2 infection.

Experimental design: We systematically analyzed plasma proteomes of COVID-19 patients from Turkey by using mass spectrometry. Different severity grades (moderate, severe, and critical) and periods of disease (early, inflammatory, and recovery) are monitored. Significant alterations in protein expressions are used to reconstruct the COVID-19 associated network that was further extended to connect viral and host proteins.

Results: Across all COVID-19 patients, 111 differentially expressed proteins were found, of which 28 proteins were unique to our study mainly enriching in immunoglobulin production. By monitoring different severity grades and periods of disease, CLEC3B, MST1, and ITIH2 were identified as potential early predictors of COVID-19 severity. Most importantly, we extended the COVID-19 associated network with viral proteins and showed the connectedness of viral proteins with human proteins. The most connected viral protein ORF8, which has a role in immune evasion, targets many host proteins tightly connected to the deregulated human plasma proteins.

Conclusions and clinical relevance: Plasma proteomes from critical patients are intrinsically clustered in a distinct group than severe and moderate patients. Importantly, we did not recover any grouping based on the infection period, suggesting their distinct proteome even in the recovery phase. The new potential early severity markers can be further studied for their value in the clinics to monitor COVID-19 prognosis. Beyond the list of plasma proteins, our disease-associated network unravels altered pathways, and the possible therapeutic targets in SARS-CoV-2 infection by connecting human and viral proteins. Follow-up studies on the disease associated network that we propose here will be useful to determine molecular details of viral perturbation and to address how the infection affects human physiology.

目的:2019冠状病毒病(COVID-19)继续威胁全球公共卫生。严重急性呼吸道冠状病毒2型(SARS-CoV-2)感染依赖性宿主细胞信号网络的改变可能揭示潜在的靶蛋白和治疗策略途径。在本研究中,我们旨在确定SARS-CoV-2感染过程中的早期严重程度生物标志物并监测其改变的途径。实验设计:采用质谱法系统分析来自土耳其的COVID-19患者的血浆蛋白质组。监测不同的严重等级(中度、重度和危重)和疾病时期(早期、炎症期和恢复期)。蛋白表达的显著变化被用来重建COVID-19相关网络,该网络被进一步扩展以连接病毒和宿主蛋白。结果:在所有COVID-19患者中发现111个差异表达蛋白,其中28个是本研究特有的蛋白,主要富集于免疫球蛋白的产生。通过监测不同的严重程度和疾病时期,cle3b、MST1和ITIH2被确定为COVID-19严重程度的潜在早期预测因子。最重要的是,我们用病毒蛋白扩展了COVID-19相关网络,并展示了病毒蛋白与人类蛋白的连通性。联系最紧密的病毒蛋白ORF8在免疫逃避中起作用,它针对许多与不受调节的人类血浆蛋白紧密相连的宿主蛋白。结论和临床意义:危重患者的血浆蛋白质组本质上与重症和中度患者聚集在一个不同的组中。重要的是,我们没有根据感染期恢复任何分组,这表明即使在恢复阶段它们的蛋白质组也不同。新的潜在早期严重程度标志物在临床监测COVID-19预后中的价值有待进一步研究。除了血浆蛋白列表之外,我们的疾病相关网络通过连接人类和病毒蛋白,揭示了改变的途径,以及SARS-CoV-2感染中可能的治疗靶点。我们在这里提出的疾病相关网络的后续研究将有助于确定病毒扰动的分子细节,并解决感染如何影响人体生理。
{"title":"Plasma proteomics identify potential severity biomarkers from COVID-19 associated network.","authors":"Ayse Tugce Sahin,&nbsp;Ali Yurtseven,&nbsp;Sina Dadmand,&nbsp;Gulin Ozcan,&nbsp;Busra A Akarlar,&nbsp;Nazli Ezgi Ozkan Kucuk,&nbsp;Aydanur Senturk,&nbsp;Onder Ergonul,&nbsp;Fusun Can,&nbsp;Nurcan Tuncbag,&nbsp;Nurhan Ozlu","doi":"10.1002/prca.202200070","DOIUrl":"https://doi.org/10.1002/prca.202200070","url":null,"abstract":"<p><strong>Purpose: </strong>Coronavirus disease 2019 (COVID-19) continues to threaten public health globally. Severe acute respiratory coronavirus type 2 (SARS-CoV-2) infection-dependent alterations in the host cell signaling network may unveil potential target proteins and pathways for therapeutic strategies. In this study, we aim to define early severity biomarkers and monitor altered pathways in the course of SARS-CoV-2 infection.</p><p><strong>Experimental design: </strong>We systematically analyzed plasma proteomes of COVID-19 patients from Turkey by using mass spectrometry. Different severity grades (moderate, severe, and critical) and periods of disease (early, inflammatory, and recovery) are monitored. Significant alterations in protein expressions are used to reconstruct the COVID-19 associated network that was further extended to connect viral and host proteins.</p><p><strong>Results: </strong>Across all COVID-19 patients, 111 differentially expressed proteins were found, of which 28 proteins were unique to our study mainly enriching in immunoglobulin production. By monitoring different severity grades and periods of disease, CLEC3B, MST1, and ITIH2 were identified as potential early predictors of COVID-19 severity. Most importantly, we extended the COVID-19 associated network with viral proteins and showed the connectedness of viral proteins with human proteins. The most connected viral protein ORF8, which has a role in immune evasion, targets many host proteins tightly connected to the deregulated human plasma proteins.</p><p><strong>Conclusions and clinical relevance: </strong>Plasma proteomes from critical patients are intrinsically clustered in a distinct group than severe and moderate patients. Importantly, we did not recover any grouping based on the infection period, suggesting their distinct proteome even in the recovery phase. The new potential early severity markers can be further studied for their value in the clinics to monitor COVID-19 prognosis. Beyond the list of plasma proteins, our disease-associated network unravels altered pathways, and the possible therapeutic targets in SARS-CoV-2 infection by connecting human and viral proteins. Follow-up studies on the disease associated network that we propose here will be useful to determine molecular details of viral perturbation and to address how the infection affects human physiology.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874836/pdf/PRCA-9999-2200070.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9635383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Protein sample preparation for tissue distribution study. 组织分布研究的蛋白质样品制备。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-03-01 DOI: 10.1002/prca.202200088
Linjia Cheng, Yilu Xu, Kangling Zhu, Bin Liang, Shuyan Zhang, Pingsheng Liu

Purpose: The distribution and expression level of a protein among animal tissues is indicative of its possible roles. It is important to establish a generally applicable method to prepare protein samples with high-quality and achieve near 100% recovery of proteins from animal tissues.

Experimental design: During preparation, to sufficiently dissolve and maintain stability of almost all proteins from tissues, as well as to avoid most contaminations affecting protein detection, 2×SDS Sample Buffer, sonication and trichloroacetic acid precipitation are applied.

Results: Here we provide a relatively simple, reproducible, and broadly applicable method for studying protein distribution in most tissues, in which the issues resulting from protein degradation and modification during sample preparation and assay interference by other cellular components like neutral lipids and glycogen could be overcome. Furthermore, this method represents the protein content by equal wet tissue mass, which is a better means to present the expression level of a protein in various tissues. High-quality protein samples from almost all tissues could be prepared.

Conclusions and clinical relevance: The samples produced are amenable to tissue distribution analysis by Western blotting and for silver/Coomassie staining, proteomics, and other protein analyses, which would contribute to potential biomarkers or treatments for a disease.

目的:研究一种蛋白在动物组织中的分布和表达水平,提示其可能的作用。建立一种普遍适用的方法来制备高质量的蛋白质样品,并从动物组织中获得接近100%的蛋白质回收率是很重要的。实验设计:在制备过程中,为了充分溶解和保持组织中几乎所有蛋白质的稳定性,同时避免大多数影响蛋白质检测的污染物,使用2×SDS样品缓冲液、超声和三氯乙酸沉淀。结果:我们提供了一种相对简单、可重复、广泛适用的方法来研究蛋白质在大多数组织中的分布,该方法可以克服样品制备过程中蛋白质降解和修饰以及其他细胞成分(如中性脂质和糖原)对分析的干扰。此外,该方法以等湿组织质量表示蛋白质含量,是一种较好的表达蛋白质在各种组织中的表达水平的方法。可以制备几乎所有组织的高质量蛋白质样品。结论和临床意义:生产的样品适用于组织分布分析,如免疫印迹、银/考马斯色染色、蛋白质组学和其他蛋白质分析,这将有助于潜在的生物标志物或疾病的治疗。
{"title":"Protein sample preparation for tissue distribution study.","authors":"Linjia Cheng,&nbsp;Yilu Xu,&nbsp;Kangling Zhu,&nbsp;Bin Liang,&nbsp;Shuyan Zhang,&nbsp;Pingsheng Liu","doi":"10.1002/prca.202200088","DOIUrl":"https://doi.org/10.1002/prca.202200088","url":null,"abstract":"<p><strong>Purpose: </strong>The distribution and expression level of a protein among animal tissues is indicative of its possible roles. It is important to establish a generally applicable method to prepare protein samples with high-quality and achieve near 100% recovery of proteins from animal tissues.</p><p><strong>Experimental design: </strong>During preparation, to sufficiently dissolve and maintain stability of almost all proteins from tissues, as well as to avoid most contaminations affecting protein detection, 2×SDS Sample Buffer, sonication and trichloroacetic acid precipitation are applied.</p><p><strong>Results: </strong>Here we provide a relatively simple, reproducible, and broadly applicable method for studying protein distribution in most tissues, in which the issues resulting from protein degradation and modification during sample preparation and assay interference by other cellular components like neutral lipids and glycogen could be overcome. Furthermore, this method represents the protein content by equal wet tissue mass, which is a better means to present the expression level of a protein in various tissues. High-quality protein samples from almost all tissues could be prepared.</p><p><strong>Conclusions and clinical relevance: </strong>The samples produced are amenable to tissue distribution analysis by Western blotting and for silver/Coomassie staining, proteomics, and other protein analyses, which would contribute to potential biomarkers or treatments for a disease.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomics of azoospermia: Towards the discovery of reliable markers for non-invasive diagnosis. 无精子症的蛋白质组学:寻找可靠的非侵入性诊断标记。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202200060
Aleksandar Rusevski, Dijana Plaseska-Karanfilska, Katarina Davalieva

Purpose: Azoospermia, as the most severe form of male infertility, no longer indicates sterility due to modern medical advancements. The current diagnostic procedure based on testicular biopsy has several drawbacks which urges the development of novel, non-invasive diagnostic procedures based on biomarkers. In the last two decades, there have been many proteomics studies investigating potential azoospermia biomarkers. In this review, we aimed to provide a critical evaluation of these studies.

Experimental design: Published articles were gathered by systematic literature search using Pubmed, Science Direct, and Google Scholar databases until March 2022 and were further preselected to include only studies on human samples.

Results: A detailed review of these studies encompassed the proteomics platforms, sources of material, proposed candidate biomarkers, and their potential diagnostic specificity and sensitivity. In addition, emphasis was put on the top, most identified and validated biomarker candidates and their potential for discriminating azoospermia types and subtypes as well as predicting sperm retrieval success rate.

Conclusions: Proteomics research of azoospermia has laid the groundwork for the development of a more streamlined biomarker testing. The future research should be focused on well-designed studies including samples from all types/subtypes as well as further testing of the most promising biomarkers identified so far.

目的:无精子症作为男性不育症最严重的形式,由于现代医学的进步,不再意味着不育。目前基于睾丸活检的诊断程序有几个缺点,这促使基于生物标志物的新型非侵入性诊断程序的发展。在过去的二十年中,有许多蛋白质组学研究调查了潜在的无精子症生物标志物。在这篇综述中,我们旨在对这些研究进行批判性评价。实验设计:通过使用Pubmed、Science Direct和Google Scholar数据库进行系统文献检索收集已发表的文章,直到2022年3月,并进一步预选,仅包括对人类样本的研究。结果:对这些研究进行了详细的回顾,包括蛋白质组学平台、材料来源、提出的候选生物标志物及其潜在的诊断特异性和敏感性。此外,重点放在了最重要的,大多数鉴定和验证的生物标志物候选物及其在区分无精子症类型和亚型以及预测精子恢复成功率方面的潜力。结论:无精子症的蛋白质组学研究为开发更精简的生物标志物检测奠定了基础。未来的研究应该集中在设计良好的研究上,包括所有类型/亚型的样本,以及对迄今为止发现的最有希望的生物标志物的进一步测试。
{"title":"Proteomics of azoospermia: Towards the discovery of reliable markers for non-invasive diagnosis.","authors":"Aleksandar Rusevski,&nbsp;Dijana Plaseska-Karanfilska,&nbsp;Katarina Davalieva","doi":"10.1002/prca.202200060","DOIUrl":"https://doi.org/10.1002/prca.202200060","url":null,"abstract":"<p><strong>Purpose: </strong>Azoospermia, as the most severe form of male infertility, no longer indicates sterility due to modern medical advancements. The current diagnostic procedure based on testicular biopsy has several drawbacks which urges the development of novel, non-invasive diagnostic procedures based on biomarkers. In the last two decades, there have been many proteomics studies investigating potential azoospermia biomarkers. In this review, we aimed to provide a critical evaluation of these studies.</p><p><strong>Experimental design: </strong>Published articles were gathered by systematic literature search using Pubmed, Science Direct, and Google Scholar databases until March 2022 and were further preselected to include only studies on human samples.</p><p><strong>Results: </strong>A detailed review of these studies encompassed the proteomics platforms, sources of material, proposed candidate biomarkers, and their potential diagnostic specificity and sensitivity. In addition, emphasis was put on the top, most identified and validated biomarker candidates and their potential for discriminating azoospermia types and subtypes as well as predicting sperm retrieval success rate.</p><p><strong>Conclusions: </strong>Proteomics research of azoospermia has laid the groundwork for the development of a more streamlined biomarker testing. The future research should be focused on well-designed studies including samples from all types/subtypes as well as further testing of the most promising biomarkers identified so far.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10849645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Tandem mass tag-based quantitative proteomic analysis of cervical cancer. 基于串联质量标记的宫颈癌定量蛋白质组学分析。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202100105
Mohammed F Aljawad, Abdul Hussein M Al Faisal, Mohammed F Alqanbar, Phillip A Wilmarth, Basima Q Hassan

Background: Cervical cancer is a common cancer in women caused by high-risk human papillomavirus (Hr-HPV). Many potential biomarkers have been proposed for precancerous lesions and cancer diagnosis and some of these markers studied for prognosis. This study determined potential biomarkers for cervical cancer diagnosis in regard to HPV genotype by using isobaric labeling quantitative proteomics.

Methods: in the current study, there were 75 formalin fixed paraffin embedded (FFPE) uterine cervical samples that used to determine the 14 HPV genotypes and the viral load of each genotype was determined. The tandem mass tag (TMT) proteomic work was performed on four FFPE samples of cervical cancer and four FFPE of control samples. The validation of biomarkers from cervical proteome were evaluated using Immunohistochemistry (IHC) testing.

Results: The most frequent HPV genotype among all other genotypes was HPV 16. There were 2753 proteins quantified by TMT and 336 of these proteins had significant differential abundances. KPNA2, MCM2, COL1A1, and DCN were selected based on functional enrichment analysis and validated by Immunohistochemistry (IHC) testing. The staining of IHC confirmed the upregulation of KPNA2 and MCM2 expression in cervical neoplasia and the downregulation of DCN and COL1A1 in some cervical cancer group subjects.

Conclusion: The KPNA2 marker was compared to other previously reported biomarkers and is a putative biomarker to be validated in further studies, specifically the relationship with HPV load.

背景:宫颈癌是由高危人乳头瘤病毒(Hr-HPV)引起的女性常见癌症。许多潜在的生物标志物已被提出用于癌前病变和癌症诊断,其中一些标志物被研究用于预后。本研究通过使用等压标记定量蛋白质组学确定宫颈癌诊断中与HPV基因型相关的潜在生物标志物。方法:本研究选取75份福尔马林固定石蜡包埋(FFPE)宫颈标本,用于检测14种HPV基因型,并测定每种基因型的病毒载量。对4例宫颈癌FFPE样本和4例对照组FFPE样本进行串联质量标签(TMT)蛋白质组学研究。应用免疫组织化学(IHC)检测评估宫颈蛋白质组生物标志物的有效性。结果:在所有基因型中,HPV基因型以hpv16最为常见。共有2753个蛋白被TMT定量,其中336个蛋白丰度差异显著。根据功能富集分析选择KPNA2、MCM2、COL1A1和DCN,并通过免疫组化(IHC)检测进行验证。免疫组化染色证实宫颈肿瘤组织中KPNA2、MCM2表达上调,部分宫颈癌组患者DCN、COL1A1表达下调。结论:KPNA2标记物与其他先前报道的生物标记物进行了比较,并且是一个假定的生物标记物,需要在进一步的研究中验证,特别是与HPV载量的关系。
{"title":"Tandem mass tag-based quantitative proteomic analysis of cervical cancer.","authors":"Mohammed F Aljawad,&nbsp;Abdul Hussein M Al Faisal,&nbsp;Mohammed F Alqanbar,&nbsp;Phillip A Wilmarth,&nbsp;Basima Q Hassan","doi":"10.1002/prca.202100105","DOIUrl":"https://doi.org/10.1002/prca.202100105","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a common cancer in women caused by high-risk human papillomavirus (Hr-HPV). Many potential biomarkers have been proposed for precancerous lesions and cancer diagnosis and some of these markers studied for prognosis. This study determined potential biomarkers for cervical cancer diagnosis in regard to HPV genotype by using isobaric labeling quantitative proteomics.</p><p><strong>Methods: </strong>in the current study, there were 75 formalin fixed paraffin embedded (FFPE) uterine cervical samples that used to determine the 14 HPV genotypes and the viral load of each genotype was determined. The tandem mass tag (TMT) proteomic work was performed on four FFPE samples of cervical cancer and four FFPE of control samples. The validation of biomarkers from cervical proteome were evaluated using Immunohistochemistry (IHC) testing.</p><p><strong>Results: </strong>The most frequent HPV genotype among all other genotypes was HPV 16. There were 2753 proteins quantified by TMT and 336 of these proteins had significant differential abundances. KPNA2, MCM2, COL1A1, and DCN were selected based on functional enrichment analysis and validated by Immunohistochemistry (IHC) testing. The staining of IHC confirmed the upregulation of KPNA2 and MCM2 expression in cervical neoplasia and the downregulation of DCN and COL1A1 in some cervical cancer group subjects.</p><p><strong>Conclusion: </strong>The KPNA2 marker was compared to other previously reported biomarkers and is a putative biomarker to be validated in further studies, specifically the relationship with HPV load.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Masthead: Proteomics 1'23 报头:Proteomics 1'23
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202370013
{"title":"Masthead: Proteomics 1'23","authors":"","doi":"10.1002/prca.202370013","DOIUrl":"https://doi.org/10.1002/prca.202370013","url":null,"abstract":"","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88762008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress in protein microarrays: Focussing on cancer research. 蛋白质微阵列的研究进展:聚焦于癌症研究。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202200036
Guang Chen, Lina Yang, Guoxiang Liu, Yunfan Zhu, Fanghao Yang, Xiaolei Dong, Fenghua Xu, Feng Zhu, Can Cao, Di Zhong, Shuang Li, Huhu Zhang, Bing Li

Although several effective treatment modalities have been developed for cancers, the morbidity and mortality associated with cancer continues to increase every year. As one of the most exciting emerging technologies, protein microarrays represent a powerful tool in the field of cancer research because of their advantages such as high throughput, small sample usage, more flexibility, high sensitivity and direct readout of results. In this review, we focus on the research progress in four types of protein microarrays (proteome microarray, antibody microarray, lectin microarray and reversed protein array) with emphasis on their application in cancer research. Finally, we discuss the current challenges faced by protein microarrays and directions for future developments. We firmly believe that this novel systems biology research tool holds immense potential in cancer research and will become an irreplaceable tool in this field.

虽然已经开发出几种有效的癌症治疗方式,但与癌症相关的发病率和死亡率每年都在增加。作为最令人兴奋的新兴技术之一,蛋白质微阵列以其高通量、小样本使用、更灵活、高灵敏度和结果直接读出等优势,成为癌症研究领域的有力工具。本文综述了蛋白质组芯片、抗体芯片、凝集素芯片和反向蛋白质芯片这四种蛋白质芯片的研究进展,重点介绍了它们在癌症研究中的应用。最后,我们讨论了蛋白质微阵列目前面临的挑战和未来的发展方向。我们坚信,这种新颖的系统生物学研究工具在癌症研究中具有巨大的潜力,将成为该领域不可替代的工具。
{"title":"Research progress in protein microarrays: Focussing on cancer research.","authors":"Guang Chen,&nbsp;Lina Yang,&nbsp;Guoxiang Liu,&nbsp;Yunfan Zhu,&nbsp;Fanghao Yang,&nbsp;Xiaolei Dong,&nbsp;Fenghua Xu,&nbsp;Feng Zhu,&nbsp;Can Cao,&nbsp;Di Zhong,&nbsp;Shuang Li,&nbsp;Huhu Zhang,&nbsp;Bing Li","doi":"10.1002/prca.202200036","DOIUrl":"https://doi.org/10.1002/prca.202200036","url":null,"abstract":"<p><p>Although several effective treatment modalities have been developed for cancers, the morbidity and mortality associated with cancer continues to increase every year. As one of the most exciting emerging technologies, protein microarrays represent a powerful tool in the field of cancer research because of their advantages such as high throughput, small sample usage, more flexibility, high sensitivity and direct readout of results. In this review, we focus on the research progress in four types of protein microarrays (proteome microarray, antibody microarray, lectin microarray and reversed protein array) with emphasis on their application in cancer research. Finally, we discuss the current challenges faced by protein microarrays and directions for future developments. We firmly believe that this novel systems biology research tool holds immense potential in cancer research and will become an irreplaceable tool in this field.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9095788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue. 局部晚期直肠癌新辅助放化疗前后的初步蛋白质组学研究表明,无反应的肿瘤组织中代谢活性高。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202100116
Tamara Babic, Vasiliki Lygirou, Jovana Rosic, Marko Miladinov, Aleksandra Djikic Rom, Eirini Baira, Rafael Stroggilos, Eftychia Pappa, Jerome Zoidakis, Zoran Krivokapic, Aleksandra Nikolic

Purpose: In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT.

Experimental design: The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses.

Result: Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only.

Conclusions and clinical relevance: Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.

目的:在寻找候选的预测性生物标志物来评估直肠癌对新辅助放化疗(nCRT)的反应时,只有少数研究报道了nCRT前后肿瘤组织的蛋白质组学特征。我们研究的目的是在治疗前后确定反应者和无反应者之间的差异表达蛋白,以确定预测和随访nCRT反应的候选分子。实验设计:本研究纳入了局部晚期直肠癌患者nCRT前后5例有应答者和5例无应答者的直肠肿瘤和非肿瘤粘膜组织切片。提取的蛋白质进行LC-MS/MS分析,然后进行一组生物信息学分析。结果:蛋白质组学分析提供了平均约1050个蛋白质鉴定每个样品。反应者和无反应者之间的蛋白质组学谱比较已经确定了18个差异表达的蛋白质。途径分析显示,在nCRT之前,无反应的肿瘤中存在高代谢活性,表明这些受试者存在内在的放化疗耐药。两种与结直肠癌预后不良相关的蛋白ADAM10和CAD被确定为候选预测生物标志物,因为它们仅存在于无反应者中。结论和临床意义:我们研究中的候选蛋白应进一步验证其作为候选生物标志物对常规应用的nCRT方案的反应。
{"title":"Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue.","authors":"Tamara Babic,&nbsp;Vasiliki Lygirou,&nbsp;Jovana Rosic,&nbsp;Marko Miladinov,&nbsp;Aleksandra Djikic Rom,&nbsp;Eirini Baira,&nbsp;Rafael Stroggilos,&nbsp;Eftychia Pappa,&nbsp;Jerome Zoidakis,&nbsp;Zoran Krivokapic,&nbsp;Aleksandra Nikolic","doi":"10.1002/prca.202100116","DOIUrl":"https://doi.org/10.1002/prca.202100116","url":null,"abstract":"<p><strong>Purpose: </strong>In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT.</p><p><strong>Experimental design: </strong>The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses.</p><p><strong>Result: </strong>Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only.</p><p><strong>Conclusions and clinical relevance: </strong>Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10574921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Development of multiple reaction monitoring (MRM) assays to identify Brucella abortus proteins in the serum of humans and livestock. 建立多反应监测(MRM)方法鉴定人畜血清中的流产布鲁氏菌蛋白。
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202200009
Aliabbas A Husain, Sneha M Pinto, Yashwanth Subbannayya, Saketh Kapoor, Payal Khulkhule, Nidhi Bhartiya, T S Keshava Prasad, Hatim F Daginawala, Lokendra R Singh, Rajpal Singh Kashyap

In the present study, a targeted multiple reaction monitoring-mass spectrometry (MRM-MS) approach was developed to screen and identify protein biomarkers for brucellosis in humans and livestock. The selection of proteotypic peptides was carried out by generating in silico tryptic peptides of the Brucella proteome. Using bioinformatics analysis, 30 synthetic peptides corresponding to 10 immunodominant Brucella abortus proteins were generated. MRM-MS assays for the accurate detection of these peptides were optimized using 117 serum samples of human and livestock stratified as clinically confirmed (45), suspected (62), and control (10). Using high throughput MRM assays, transitions for four peptides were identified in several clinically confirmed and suspected human and livestock serum samples. Of these, peptide NAIYDVVTR corresponding to B. abortus proteins: BruAb2_0537 was consistently detected in the clinically confirmed serum samples of both humans and livestock with 100% specificity. To conclude, a high throughput MRM-MS-based protocol for detecting endogenous B. abortus peptides in serum samples of humans and livestock was developed. The developed protocol will help design sensitive assays to accurately diagnose brucellosis in humans and livestock. The data associated with this study are deposited in Panorama Public (https://panoramaweb.org/rNOZCy.url with ProteomeXchange ID: PXD034407).

在本研究中,开发了一种靶向多反应监测-质谱(MRM-MS)方法来筛选和鉴定人类和牲畜布鲁氏菌病的蛋白质生物标志物。蛋白质型肽的选择是通过生成布鲁氏菌蛋白质组的硅质色氨酸进行的。通过生物信息学分析,合成了与10种免疫优势布鲁氏菌蛋白对应的30条合成肽。对117份人类和牲畜血清样本进行了优化,将其分为临床确诊(45份)、疑似(62份)和对照(10份),以准确检测这些肽。利用高通量MRM分析,在几个临床证实和疑似的人和牲畜血清样本中鉴定了四种肽的转变。其中,与abortus B.蛋白BruAb2_0537对应的肽段NAIYDVVTR在临床确认的人畜血清样本中均被检测到,特异性为100%。最后,建立了一种基于mrm - ms的高通量检测人畜血清中内源性流产杆菌肽的方法。制定的方案将有助于设计敏感的检测方法,以准确诊断人类和牲畜中的布鲁氏菌病。与本研究相关的数据保存在Panorama Public (https://panoramaweb.org/rNOZCy.url, ProteomeXchange ID: PXD034407)中。
{"title":"Development of multiple reaction monitoring (MRM) assays to identify Brucella abortus proteins in the serum of humans and livestock.","authors":"Aliabbas A Husain,&nbsp;Sneha M Pinto,&nbsp;Yashwanth Subbannayya,&nbsp;Saketh Kapoor,&nbsp;Payal Khulkhule,&nbsp;Nidhi Bhartiya,&nbsp;T S Keshava Prasad,&nbsp;Hatim F Daginawala,&nbsp;Lokendra R Singh,&nbsp;Rajpal Singh Kashyap","doi":"10.1002/prca.202200009","DOIUrl":"https://doi.org/10.1002/prca.202200009","url":null,"abstract":"<p><p>In the present study, a targeted multiple reaction monitoring-mass spectrometry (MRM-MS) approach was developed to screen and identify protein biomarkers for brucellosis in humans and livestock. The selection of proteotypic peptides was carried out by generating in silico tryptic peptides of the Brucella proteome. Using bioinformatics analysis, 30 synthetic peptides corresponding to 10 immunodominant Brucella abortus proteins were generated. MRM-MS assays for the accurate detection of these peptides were optimized using 117 serum samples of human and livestock stratified as clinically confirmed (45), suspected (62), and control (10). Using high throughput MRM assays, transitions for four peptides were identified in several clinically confirmed and suspected human and livestock serum samples. Of these, peptide NAIYDVVTR corresponding to B. abortus proteins: BruAb2_0537 was consistently detected in the clinically confirmed serum samples of both humans and livestock with 100% specificity. To conclude, a high throughput MRM-MS-based protocol for detecting endogenous B. abortus peptides in serum samples of humans and livestock was developed. The developed protocol will help design sensitive assays to accurately diagnose brucellosis in humans and livestock. The data associated with this study are deposited in Panorama Public (https://panoramaweb.org/rNOZCy.url with ProteomeXchange ID: PXD034407).</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10568939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Proteomic and lipidomic biomarkers in the diagnosis and progression of inflammatory bowel disease - a review. 炎症性肠病诊断和进展中的蛋白质组学和脂质组学生物标志物综述
IF 2 4区 生物学 Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.1002/prca.202200003
Elżbieta Cecerska-Heryć, Bartosz Ronkowski, Rafał Heryć, Natalia Serwin, Bartłomiej Grygorcewicz, Marta Roszak, Katarzyna Galant, Barbara Dołęgowska

Purpose: There is an increasing prevalence of inflammatory bowel disease (IBD) and to date, no effective treatment has been developed and the exact etiology of this disease remains unknown. Nevertheless, a growing number of proteomic and lipidomic studies have identified certain proteins and lipids which can be used successfully in patients to improve diagnoses and monitoring of treatment.

Experimental design: We have focused on the applications of proteins and lipids for IBD diagnostics, including differentiation of Crohn's disease (CD) and ulcerative colitis (UC), treatment monitoring, monitoring of clinical state, likelihood of relapse, and their potential for novel targeted treatments.

Results: Analysis of protein and lipid profiles can: improve the availability and use of diagnostic markers; improve understanding of the pathomechanisms of IBD, for example, several studies have implicated platelet dysfunction (PF4), autoimmune responses (granzyme B, perforin), and abnormal metabolism (arachidonic acid pathways); aid in monitoring patient health; and improve therapeutics (experimental phosphatidylcholine therapy has been shown to result in an improvement in intestinal condition).

Conclusions: Despite the enormous progress of proteomics and lipidomics in recent years and the development of new technologies, further research is needed to select some of the most sensitive and specific markers applicable in diagnosing and treating IBD.

目的:炎症性肠病(IBD)的患病率越来越高,迄今为止,尚未开发出有效的治疗方法,该疾病的确切病因尚不清楚。然而,越来越多的蛋白质组学和脂质组学研究已经确定了某些蛋白质和脂质,这些蛋白质和脂质可以成功地用于患者,以改善诊断和监测治疗。实验设计:我们专注于蛋白质和脂质在IBD诊断中的应用,包括克罗恩病(CD)和溃疡性结肠炎(UC)的鉴别、治疗监测、临床状态监测、复发可能性以及它们作为新型靶向治疗的潜力。结果:蛋白和脂质谱分析可以提高诊断标志物的可得性和使用率;提高对IBD病理机制的理解,例如,一些研究已经涉及血小板功能障碍(PF4)、自身免疫反应(颗粒酶B、穿孔素)和代谢异常(花生四烯酸途径);协助监测病人的健康状况;改善治疗方法(实验性磷脂酰胆碱疗法已被证明能改善肠道状况)。结论:尽管近年来蛋白质组学和脂质组学取得了巨大进展,新技术不断发展,但仍需要进一步研究,以选择一些最敏感、最特异的标志物,适用于IBD的诊断和治疗。
{"title":"Proteomic and lipidomic biomarkers in the diagnosis and progression of inflammatory bowel disease - a review.","authors":"Elżbieta Cecerska-Heryć,&nbsp;Bartosz Ronkowski,&nbsp;Rafał Heryć,&nbsp;Natalia Serwin,&nbsp;Bartłomiej Grygorcewicz,&nbsp;Marta Roszak,&nbsp;Katarzyna Galant,&nbsp;Barbara Dołęgowska","doi":"10.1002/prca.202200003","DOIUrl":"https://doi.org/10.1002/prca.202200003","url":null,"abstract":"<p><strong>Purpose: </strong>There is an increasing prevalence of inflammatory bowel disease (IBD) and to date, no effective treatment has been developed and the exact etiology of this disease remains unknown. Nevertheless, a growing number of proteomic and lipidomic studies have identified certain proteins and lipids which can be used successfully in patients to improve diagnoses and monitoring of treatment.</p><p><strong>Experimental design: </strong>We have focused on the applications of proteins and lipids for IBD diagnostics, including differentiation of Crohn's disease (CD) and ulcerative colitis (UC), treatment monitoring, monitoring of clinical state, likelihood of relapse, and their potential for novel targeted treatments.</p><p><strong>Results: </strong>Analysis of protein and lipid profiles can: improve the availability and use of diagnostic markers; improve understanding of the pathomechanisms of IBD, for example, several studies have implicated platelet dysfunction (PF4), autoimmune responses (granzyme B, perforin), and abnormal metabolism (arachidonic acid pathways); aid in monitoring patient health; and improve therapeutics (experimental phosphatidylcholine therapy has been shown to result in an improvement in intestinal condition).</p><p><strong>Conclusions: </strong>Despite the enormous progress of proteomics and lipidomics in recent years and the development of new technologies, further research is needed to select some of the most sensitive and specific markers applicable in diagnosing and treating IBD.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10568974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
PROTEOMICS – Clinical Applications
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1